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The transcription factor p53 is the best-known tumor suppressor, but its sibling p63 is a 28 
master regulator of epidermis development and a key oncogenic driver in squamous cell 29 
carcinomas (SCC). Despite multiple gene expression studies becoming available, the limited 30 
overlap of reported p63-dependent genes has made it difficult to decipher the p63 gene 31 
regulatory network. Particularly, analyses of p63 response elements differed substantially 32 
among the studies. To address this intricate data situation, we provide an integrated 33 
resource that enables assessing the p63-dependent regulation of any human gene of 34 
interest. We use a novel iterative de novo motif search approach in conjunction with 35 
extensive ChIP-seq data to achieve a precise global distinction between p53 and p63 binding 36 
sites, recognition motifs, and potential co-factors. We integrate these data with 37 
enhancer:gene associations to predict p63 target genes and identify those that are 38 
commonly de-regulated in SCC representing candidates for prognosis and therapeutic 39 
interventions.  40 
 41 
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In contrast to the tumor suppressor p53 with its extensive set of target genes 47 
controlling the cell cycle and apoptosis (Fischer, 2017; Sammons et al., 2020), its 48 
phylogenetically ancient sibling p63 (ΔNp63) governs epidermis development (Mills et al., 49 
1999; Yang et al., 1999) and is an oncogenic driver of squamous cell carcinoma (SCC) 50 
(Campbell et al., 2018; Gatti et al., 2019) that is overexpressed or amplified in SCCs, which 51 
depend on its expression (Ramsey et al., 2013). Together with p73, p63 and p53 form the 52 
p53 transcription factor (TF) family that shares a highly conserved DNA binding domain 53 
(DBD) through which they bind to very similar DNA recognition motifs. The mechanisms that 54 
enable these sibling TFs to shape their unique gene regulatory network (GRN) leading to the 55 
different phenotypic control, however, remain poorly understood. 56 
The TP53 and TP63 genes encode for two major isoform groups that are controlled by 57 
distinct promoters leading to transcripts differing in their N-terminus (Murray-Zmijewski et al., 58 
2006). In the case of TP53, the longest isoform, p53α, is ubiquitously expressed while the 59 
alternative intronic promoter has little activity across virtually all tissues. Conversely, the 60 
usage of the two TP63 promoters is highly cell type-dependent. For instance, the long 61 
isoform TAp63 is predominantly expressed in germ cells, while the smaller transcript, ΔNp63, 62 
is most copious in stratifying epithelia (Sethi et al., 2015). Similar to p53, alternative splicing 63 
leads to α, β, and γ protein isoforms that differ in their C-terminus (Murray-Zmijewski et al., 64 
2006). While both TAp63 and ΔNp63 may bind to DNA through a specific binding domain, 65 
ΔNp63 lacks the canonical N-terminal transactivation domain (TAD) (Yang et al., 1998) and 66 
has long been thought to be a dominant-negative regulator of other p53 family members or 67 
its own isoforms (Gebel et al., 2016; Yang et al., 1998). However, ΔNp63 has also been 68 
shown to harbor alternative TADs, that endow transactivation activity (Helton et al., 2006; 69 
King et al., 2003; Yang et al., 2006). Notably, many ΔNp63 binding sites are associated with 70 
enhancer regions, where ΔNp63 has been proposed to “bookmark” genes that are expressed 71 
in stratifying epithelia (Karsli Uzunbas et al., 2019; Kouwenhoven et al., 2015a; Lin-Shiao et 72 
al., 2019; Qu et al., 2018; Somerville et al., 2018). Here, we focus on the most widely 73 
expressed isoforms p53α (hereafter p53) and ΔNp63 (hereafter p63). 74 
The p53 TF family shares many binding sites, but all three family members have been 75 
shown to bind to substantial sets of unique target genes (Lin et al., 2009; McDade et al., 76 
2014). Indeed, there are differences in the DBDs, e.g. regarding thermostability, hydrophobic 77 
potentials (Enthart et al., 2016), zinc-coordination (Lokshin et al., 2007), and redox sensitivity 78 
(Tichý et al., 2013). In addition, the different C-terminal domains (CTD) of p53 family 79 
members may also affect their DNA binding specificity (Sauer et al., 2008). p53 binds to a 80 
canonical 20 bp response element (RE) made of two decameric half-sites that both contain 81 
the sequence RRRCWWGYYY (R = A/G; W= A/T; Y = C/T). p53 has also been shown to 82 
bind to decameric half-sites separated by spacers or to single half-sites (Kitayner et al., 83 
2010; Menendez et al., 2013; Vyas et al., 2017). Results from systematic evolution of ligands 84 
by exponential enrichment (SELEX) (Ortt and Sinha, 2006; Perez et al., 2007) and high-85 
throughput analyses of chromatin immunoprecipitation (ChIP) (Kouwenhoven et al., 2010; 86 
McDade et al., 2012; Yang et al., 2006) yielded p63 binding motifs with high similarity to the 87 
p53RE but still showed some unique characteristics. These unique characteristics identified 88 
for p63REs, however, differed substantially between the studies.  89 
While multiple genome-wide p63 gene expression datasets became available in recent 90 
years, our understanding of the p63 GRN remains incomplete. This is in part due to the 91 
limited overlap of the p63-dependent genes identified in individual studies (Kouwenhoven et 92 
al., 2015b). Also, the frequent binding of p63 to enhancers (Kouwenhoven et al., 2015a; Lin-93 
Shiao et al., 2019, 2018; Qu et al., 2018; Somerville et al., 2018) and the difficulty to 94 
associate such enhancers with target gene regulation adds another level of complexity to the 95 
quest of describing the GRN. To overcome these limitations, we utilize a recently developed 96 
meta-analysis approach (Fischer et al., 2016a), which helped us to dissect the GRNs of the 97 
mouse and human orthologue of p53 (Fischer, 2020, 2019). The analysis rests upon a 98 
ranking of potential p63 target genes based on the number of datasets supporting a p63-99 
dependent regulation. In addition, we utilize the wealth of recent p63 and p53 ChIP-seq 100 
studies to establish a more precise global distinction between p53 and p63 binding sites and 101 
their underlying REs. This approach could serve as a blueprint to distinguish binding site 102 
specificities of TF siblings. Further integration of gene expression studies with the binding 103 





The p63 gene regulatory network 109 
To identify genes commonly regulated by p63 across cell types and tissues, we 110 
employed a previously established meta-analysis approach, that has been helpful to infer 111 
core GRNs for human and mouse p53, the viral oncoprotein E7 and the cell cycle GRN 112 
(Fischer, 2019; Fischer et al., 2017, 2016a, 2014). From 11 genome-wide studies (Abraham 113 
et al., 2018; Bao et al., 2015; Carroll et al., 2006; Gallant-Behm et al., 2012; Karsli Uzunbas 114 
et al., 2019; Lin-Shiao et al., 2019; Saladi et al., 2017; Somerville et al., 2018; Watanabe et 115 
al., 2014; Wu et al., 2012; Zarnegar et al., 2012) (Supplementary File 1), 16 publically 116 
available gene expression datasets were integrated to generate a specific p63 Expression 117 
Score (Supplementary File 2). The datasets have been obtained from knockdown (n=12) or 118 
overexpression experiments (n=4) of p63 in primary keratinocytes (n=3), the keratinocyte cell 119 
line HaCaT (n=2), the foreskin fibroblast cell line BJ (n=1), the breast epithelial cell line 120 
MCF10A (n=4), the squamous carcinoma cell lines H226 (n=2), KYSE70 (n=1), and FaDu 121 
(n=1), as well as the pancreatic ductal adenocarcinoma cell lines BxPC3 (n=1) and SUIT2 122 
(n=1) (Figures 1A and 1B and Supplementary File 1).  123 
To illustrate the utility of our approach, we selected 30 genes from various p63 124 
Expression Score groups reflecting commonly up- and down-regulated ones (Figure 1C). We 125 
noted lower consistency across the data on p63-dependent gene regulation as compared to 126 
previous meta-analyses on human and mouse p53 (Fischer, 2019; Fischer et al., 2016a). In 127 
contrast to the recent investigations, data integrated here are based on a higher number of 128 
experiments in primary cells and a comparably lower number of replicates. Thus, the 129 
reduced consistency may also reflect the higher variance as opposed to data from more 130 
homogenous cell lines. Furthermore, p63-depleted cells are less viable, and the global 131 
decrease in mRNA levels may confound effects. Despite this, our approach identified genes 132 
that are commonly altered by p63. 133 
We next performed gene set enrichment analysis (GSEA) for p63-dependently 134 
regulated genes using MSigDB gene sets (Subramanian et al., 2005). In agreement with the 135 
function of p63 as an essential proliferation factor (McDade et al., 2011; Senoo et al., 2007; 136 
Truong et al., 2006), epidermal development regulator (Mills et al., 1999; Yang et al., 1999), 137 
and MYC network activator (Wu et al., 2012), we find that genes commonly up-regulated by 138 
p63 significantly enrich gene sets associated with cell cycle, epidermis development, and 139 
MYC targets (Figure 2A). In line with previous reports (Mehta et al., 2018), genes down-140 
regulated by p63 enrich gene sets connected with interferon response (Figure 2B). 141 
Corroborating the role of p63 in mammary stem cell activity (Chakrabarti et al., 2014) and 142 
SCC growth (Ramsey et al., 2013), we find that p63 up- and down-regulated genes enrich 143 
respective gene sets up- and down-regulated in mammary stem cells (Figure 2C) and across 144 
SCCs (Figure 2D). In addition to pathways that have been linked to p63 earlier, we find that 145 
p63 up-regulated genes enrich for mTORC1 signaling genes and p63 down-regulated genes 146 
enrich for gene sets associated with oxidative phosphorylation and aerobic respiration 147 
(Figure 2E). 148 
Further, we performed TF binding enrichment analysis for p63-dependently regulated 149 
genes using Enrichr (Kuleshov et al., 2016). In agreement with its established roles, we 150 
identify cell cycle gene regulators (E2F4, E2F6, SIN3A, E2F1, FOXM1, NFYA, and NFYB 151 
(Fischer and Müller, 2017)) and the MYC/MAX TFs as being enriched among p63-152 
upregulated genes. Consistent with previous reports, our analysis also identifies KLF4 (Sen 153 
et al., 2012) and SMAD4 (Calleja et al., 2016) as potential mediators of p63-dependent gene 154 
regulation. In addition, our analysis reveals that androgen receptor (AR), its co-factor ZMIZ1, 155 
as well as SP1, FLI1, and NANOG are novel candidates for mediating the p63-dependent 156 
up-regulation of multiple genes. Surprisingly, our analysis identified only SOX2 as a frequent 157 
binder of genes down-regulated by p63 (Figure 3A). Consistent with the strong association of 158 
p63 up-regulated genes with the cell cycle (Figure 2A) and with cell cycle regulators (Figure 159 
3A), we find that p63 up-regulated genes enrich DREAM (dimerization partner, RB-like, E2F, 160 
and multi-vulval class B) and E2F target genes (Figure 3B), and DREAM target genes 161 
appear to be modestly but consistently down-regulated when p63 is lost (Figure 3C). 162 
Notably, most datasets on p63-dependent gene expression were derived from cells in which 163 
p63 was overexpressed or depleted, without additional treatments. However, one dataset 164 
was derived from Nutlin-treated MCF10A cells (Karsli Uzunbas et al., 2019). MCF10A cells 165 
harbor wild-type p53 and DREAM targets are down-regulated in response to Nutlin 166 
treatment. Strikingly, depletion of p63 decreased their expression even further without 167 
affecting CDKN1A (p21) levels (Figure 3D), which indicates a possible cumulative effect that 168 
is independent of p53 regulatory functions. 169 
Together, the meta-analysis approach overcomes the limitations of individual studies 170 
and identifies target genes supported by multiple datasets. The extensive and integrated 171 
resource on p63-regulated genes enables researchers to compare their results quickly and to 172 
identify the most promising targets. 173 
 174 
p63 and p53 regulate largely distinct gene sets 175 
Given that p63 and p53 share a significant number of binding sites and thus potential 176 
target genes, we next compared the p63 Expression Score to the previously established p53 177 
Expression Score (Fischer et al., 2016a). In agreement with the up-regulation of cell cycle 178 
genes and DREAM targets through p63 (Figure 2A and 3) and their down-regulation through 179 
p53 (Fischer et al., 2016a, 2016b; Schade et al., 2019; Uxa et al., 2019), we noted that 180 
negative p53 Expression Scores tend to correlate with positive p63 Expression Scores 181 
(Figure 4A). Furthermore, the results indicate that p53-induced genes (positive p53 182 
Expression Scores) appear to be largely unaffected by p63. Consistently, expression data for 183 
343 target genes with strong evidence for direct up-regulation by p53 (Fischer, 2017), do not 184 
show consistent expression changes upon knockdown or induction of p63 (Figure 4B). 185 
Together, these results indicate that basal expression of the majority of p53 target genes is 186 
not affected by p63. 187 
 188 
Common and distinct properties of p63 and p53 DNA binding 189 
To identify shared p63 and p53 bound sites, we compared the 20 p63 ChIP-seq 190 
datasets (Supplementary File 1) to 28 p53 ChIP-seq datasets we compiled recently (Fischer, 191 
2019). Notably, p63 and p53 data was collected from cells with strong basal p63 expression 192 
and stimulated p53 expression, respectively. While the majority of all p53 ChIP-seq peaks 193 
occurs in only one of the experiments, more than half of the p63 peaks are present in two or 194 
more datasets (Figure 5A and B). Even though we were able to integrate substantially more 195 
p53 datasets, the number of identified p63 binding sites was still higher (Figure 5C). This 196 
indicates that p63 occupies many more binding sites as compared to p53. Importantly, when 197 
more datasets agree on p53 and p63 binding sites, these sequences are more likely to 198 
harbor a canonical p53 and p63RE, facilitating the motif discovery by tools such as HOMER 199 
(Heinz et al., 2010) and enriching bona fide binding sites (Figure 5D). Earlier meta-analyses 200 
employed a similar strategy (Fischer et al., 2016a; Nguyen et al., 2018; Verfaillie et al., 201 
2016). To dissect the binding preferences of p63 and p53, we generated three distinct peak 202 
sets (Figure 5E). The ‘p53+p63’ set contained all binding sites with evidence in at least five 203 
p63 and five p53 ChIP-seq datasets. The ‘p53 unique’ (hereafter ‘p53’) set contained all 204 
binding sites that were supported by at least five p53 ChIP-seq datasets but not a single p63 205 
dataset. We also generated a ‘p63 unique’ (hereafter ‘p63’) set vice versa. 206 
We employed an iterative de novo motif search using HOMER to identify frequent 207 
binding site motifs. After each round, we removed all peaks harboring the best motif and 208 
repeated the search. We identified similar yet distinct binding motifs for the three groups 209 
(Figure 5F). Comparison of the primary ‘p53+p63’, ‘p53’, and ‘p63’ motifs suggests that p63 210 
binding sites display a highly conserved C, G, C, and G at positions 4, 7, 14, and 17, 211 
respectively. The second round revealed a p53RE containing a 1bp spacer (p53 secondary 212 
motif), supporting the model that p53 can bind to spacer-containing p53REs (Vyas et al., 213 
2017). The results further indicate that p53 can bind to a single half-site (p53 tertiary motif) 214 
and that this single half-site is more constrained at positions 5 and 6 as well as the flanking 215 
regions than half-sites in the canonical p53RE (e.g. primary p53+p63 and p53 motifs). Of 216 
note, these single half-sites may also include p53REs with spacers longer than 1 bp that are 217 
not detected separately because of their very low abundance. Sole half-sites together with 218 
spacer-containing p53REs underlie only ~5 % of p53 bound sites (Figure 6). Furthermore, 219 
p53 and p63 appear to be able to bind to three-quarter sites (secondary and quaternary 220 
p53+p63 and p63 motifs), while p63 can generally bind to a broader spectrum of sequences 221 
as compared to p53 (Figure 5F). This broader binding repertoire likely underlies p63’s 222 
capacity to engage with substantially more binding sites than does p53. 223 
It is important to note that the vast majority (~70 %) of p53 and p63 binding sites 224 
harbor full-length p53 and p63REs (Figure 6 and 7, Supplementary File 3). There is a good 225 
correlation between p53 and p63 binding site occupation, and most sites commonly bound 226 
by p53 are also frequently bound by p63 (Figure 5-figure supplement 1). However, p63 binds 227 
many sites that are not bound by p53 (Figure 5E and Figure 5-figure supplement 2). More 228 
importantly, p53 binding is strongly constrained to canonical p53RE (Figure 5-figure 229 
supplement 1C-D and 2A-C). In contrast, p63 binding appears not to benefit from a more 230 
canonical p63RE (Figure 5-figure supplement 1E-F and 2D-F). These data suggest that 231 
sequence-specific binding is particularly important to recruit p53, while p63 only requires 232 
minimal sequence identity and could require additional co-factors to bind and ultimately 233 
regulate its target genes. 234 
Therefore, we also searched for potential cooperating TFs that may be co-enriched at 235 
p53 and p63 binding sites. Consistent with earlier analyses (Verfaillie et al., 2016), no 236 
additional motif was substantially enriched in the vicinity of ‘p53’ or ‘p53+p63’ binding sites. 237 
Consistent with the co-enrichment of AP-1 and p63 at enhancers (Lin-Shiao et al., 2018), we 238 
found that unique p63 binding sites were consistently enriched for AP-1 (bZIP) in addition to 239 
bHLH motifs (Figure 5-figure supplement 3). Using the CistromeDB toolkit (R. Zheng et al., 240 
2019), we identified TFs that significantly enrich for binding to the ‘p53+p63’, ‘p53’, and ‘p63’ 241 
sites. As expected, the analysis identified the p53 family members p53, p63, and p73 as best 242 
hits for the common sites, but only p53 and p73 for the unique p53 and only p63 and p73 for 243 
the unique p63 peak sets (Figure 5-figure supplement 4). In agreement with earlier studies, 244 
the analysis identified p300 (Katoh et al., 2019), MAF (Lopez-Pajares et al., 2015), SOX2 245 
(Watanabe et al., 2014), BANF1 (also known as BAF) (Bao et al., 2015), and KMT2D (Lin-246 
Shiao et al., 2018) as potential co-binders of p63; as well as TRIM28 (Doyle et al., 2010), 247 
BRD4 (Stewart et al., 2013), p300 (Lill et al., 1997), ZBTB33 (KAISO) (Koh et al., 2014), 248 
CDK9 (Claudio et al., 2006), and HEXIM1 (Lew et al., 2012) as potential co-binders of p53. 249 
Moreover, our analysis identified potential co-binders that to our knowledge have not been 250 
identified before, such as KDM1A, PRMT1, and GRHL2 for p63 and BRD9, ZNF131, and 251 
C17orf49 for p53. Importantly, these new potential co-binders appear to be unique to either 252 
p63 or p53, suggesting that they may contribute to shaping the DNA binding landscapes that 253 
are specific to p63 and p53 (Figure 5-figure supplement 4). 254 
 255 
Identification of direct p63 target genes 256 
Given that p63 regulates many target genes through enhancers (Kouwenhoven et al., 257 
2015a; Lin-Shiao et al., 2019, 2018; Qu et al., 2018; Somerville et al., 2018), straight forward 258 
integration of differential gene regulation data and p63 binding data based on proximity 259 
binding to a gene’s TSS is unlikely to capture all direct p63 target genes. To resolve this 260 
issue, we integrated the p63 binding data and the p63 Expression Score based on 261 
enhancer:gene association information (Fishilevich et al., 2017) in addition to proximity 262 
binding to TSSs to predict direct p63 target genes. Given the large number of p63 binding 263 
sites identified (Figure 5C and 5E) and the high variance in p63-dependent gene regulation 264 
(Figure 1B), we employed conservative thresholds to identify high-probability target genes of 265 
p63. We only used p63 binding sites supported by at least half of the datasets (≥10) that are 266 
linked through TSS proximity (within 5 kb) or double-elite enhancer:gene associations 267 
(Fishilevich et al., 2017) to genes with a |p63 Expression Score| ≥ 8 (Table 1 and Figure 7-268 
figure supplement 1). Of note, many genes are associated with proximal and enhancer p63 269 
binding, because many proximal promoters are also identified as double-elite enhancers in 270 
the database. The 180 (138 up-regulated and 42 down-regulated) genes that passed our 271 
conservative filtering contain many genes that are known direct p63 targets, such as RAB38 272 
(Barton et al., 2010), S100A2 (Kirschner et al., 2008; Lapi et al., 2006), HAS3 (Compagnone 273 
et al., 2017), IRF6 (Thomason et al., 2010), PTHLH (Somerville et al., 2018), GPX2 (Yan and 274 
Chen, 2006), JAG1 (Sasaki et al., 2002), MMP14 (Lodillinsky et al., 2016), NRG1 (Forster et 275 
al., 2014), and PLAC8 (Gallant-Behm et al., 2012). The identification of these well-276 
established p63 target genes indicates the ability of our approach to identify bona fide 277 
candidates. Importantly, the integration of enhancer:gene associations enabled the 278 
identification of genes that are likely regulated by p63 through enhancers, such as IL1B, 279 
MREG, MYO5A, RRP12, SNCA, AK4, and EHD4 (Table 1 and Figure 7-figure supplement 280 
1).  281 
 282 
Table 1. High-probability direct p63 target genes. Genes identified as significantly up- or 283 
down-regulated in at least the half of all datasets (|p63 Expression Score| ≥ 8) that are linked 284 
to p63 binding sites supported by at least half of all datasets (≥ 10) through binding within 5 285 
kb from their TSS or through double-elite enhancer-gene associations (Fishilevich et al., 286 
2017). Using these thresholds we identified 138 and 42 high-probability candidates as 287 
directly up- and down-regulated by p63, respectively. Gene names marked in bold are also 288 





























DUSP6 14 yes yes FSCN1 8 yes yes 
RAB38 14 yes yes GINS3 8 yes no 
GSDME 13 yes yes GM2A 8 yes yes 
LAD1 13 yes yes HMGA2 8 yes yes 
S100A2 13 yes yes HSPA4L 8 yes yes 
TMEM40 13 yes yes JAG1 8 yes yes 
FGFBP1 12 yes yes KCTD12 8 yes no 
HAS3 12 yes no KIAA0930 8 yes yes 
NECTIN1 12 yes yes KIF14 8 no yes 
TCOF1 12 yes yes KIRREL1 8 no yes 
DUSP7 11 yes yes LIG1 8 yes yes 
IL1B 11 no yes LPAR3 8 yes yes 
MREG 11 no yes LRRFIP2 8 no yes 
PA2G4 11 yes no MALT1 8 no yes 
RGS20 11 yes no MAST4 8 no yes 
SDC1 11 no yes MCM3 8 no yes 
SFN 11 yes yes MMP14 8 yes yes 
STK17A 11 yes yes MMRN2 8 yes no 
VSNL1 11 yes yes NOM1 8 yes no 
ARHGAP25 10 yes yes NRCAM 8 yes yes 
CDCA4 10 yes yes NRG1 8 no yes 
DUSP11 10 yes no OAS3 8 yes yes 
FAT2 10 yes no PPFIBP1 8 yes yes 
FERMT1 10 yes yes PROCR 8 yes no 
IL4R 10 yes yes QSOX2 8 yes yes 
INPP1 10 yes yes RAD51C 8 yes yes 
IRF6 10 no yes RASSF6 8 no yes 
ITGA6 10 no yes RFX7 8 yes no 
KIZ 10 yes no SH3PXD2A 8 no yes 
MAPKBP1 10 no yes SLC1A5 8 yes yes 
MYO10 10 yes yes SLC2A9 8 yes yes 
MYO19 10 yes yes SLC37A2 8 yes no 
ORC1 10 no yes SMAD5 8 yes no 
PAK1 10 yes no SPATS2 8 no yes 
PTHLH 10 yes yes SSRP1 8 no yes 
SMTN 10 yes no TGFB1 8 yes yes 
WDFY2 10 yes no TMEM237 8 yes no 
XDH 10 yes yes TOMM34 8 yes no 
ARHGDIB 9 yes yes TRIM7 8 yes yes 
AURKB 9 yes no TRIP13 8 yes no 
BTBD11 9 yes no TSPAN5 8 yes no 
C6orf106 9 yes no TSR1 8 no yes 
CARD10 9 yes yes TYMS 8 yes yes 
CHAF1A 9 no yes UCK2 8 yes yes 
CSTA 9 yes no UTP4 8 no yes 
CYP27B1 9 yes no YAP1 8 yes no 
FEZ1 9 yes yes YES1 8 yes yes 
GNA15 9 yes no ZFP36L2 8 no yes 
GPX2 9 yes no APH1B -8 no yes 
GSTP1 9 yes no BIRC3 -8 yes yes 
HRAS 9 yes yes C9orf3 -8 yes yes 
IFI16 9 yes yes CHST3 -8 no yes 
KREMEN1 9 yes yes CPQ -8 no yes 
LDLR 9 yes no DUSP8 -8 yes no 
MAPK6 9 yes yes EPCAM -8 no yes 
MYO5A 9 no yes ERBB2 -8 no yes 
NCAPH2 9 yes no FBN1 -8 no yes 
NDE1 9 yes yes ITFG1 -8 yes no 
NDST1 9 yes yes LLGL2 -8 yes yes 
NIPAL4 9 yes yes NCSTN -8 no yes 
PPIF 9 no yes OPN3 -8 no yes 
PPP4R4 9 yes no PBX1 -8 yes yes 
PTTG1 9 yes yes PDXK -8 no yes 
RAPGEF5 9 yes yes PLAC8 -8 yes yes 
RNASE7 9 yes yes S100A4 -8 no yes 
RRP12 9 no yes SPOCK1 -8 no yes 
SERPINB13 9 yes no TNS3 -8 no yes 
SNCA 9 no yes ARL6IP5 -9 no yes 
STX6 9 yes no COBL -9 no yes 
AK4 8 no yes CUEDC1 -9 yes yes 
ARHGAP23 8 yes yes GSN -9 yes no 
ASCC3 8 yes yes PDGFC -9 yes yes 
BRCA1 8 yes no PGPEP1 -9 no yes 
BTBD10 8 yes yes PLXNB2 -9 yes yes 
CCNK 8 yes no PXDN -9 no yes 
CCT4 8 yes no RALGPS1 -9 yes yes 
CD44 8 yes yes ROR1 -9 yes no 
CDC42SE1 8 yes no SLC16A5 -9 yes yes 
CDCA7 8 yes no TM4SF1 -9 yes yes 
COL17A1 8 yes no ALDH3B1 -10 yes yes 
CRKL 8 yes yes CYP1B1 -10 no yes 
DRAP1 8 yes yes HHAT -10 yes yes 
EHD4 8 no yes MEGF8 -10 no yes 
ERCC6L 8 no yes PTGES -10 yes no 
ESRP1 8 no yes PTTG1IP -10 no yes 
FABP5 8 yes no RPS27L -10 yes yes 
FANCI 8 yes yes SECTM1 -10 yes yes 
FLOT2 8 yes no SLC22A5 -10 yes no 
FOSL1 8 yes yes TNFSF15 -10 yes yes 
FRMD4B 8 yes no SRD5A3 -11 yes no 
 290 
 291 
A p63/SCC 28-gene set correlates with HNSC patient survival 292 
Out of the 180 high-probability p63 target genes 32 (28 up- and 4 down-regulated) 293 
are also identified as being commonly up- or down-regulated in SCCs compared to non-SCC 294 
cancers (Campbell et al., 2018) (Table 1). Importantly, several of the genes commonly up-295 
regulated by p63 as well as in SCC have been identified to promote SCC growth or invasion, 296 
such as LAD1 (Abe et al., 2019), TMEM40 (Zhang et al., 2019), FGFBP1 (Czubayko et al., 297 
1997), IL1B (Lee et al., 2015), FAT2 (Dang et al., 2016), FOSL1 (Usui et al., 2012), LPAR3 298 
(Brusevold et al., 2014), MMP14 (Pang et al., 2016), and RASSF6 (L. Zheng et al., 2019). 299 
Therefore, we asked whether the set of 28 up-regulated direct p63 targets correlates with 300 
patient survival. To this end, we employed data of head and neck SCC (HNSC) patients from 301 
The Cancer Genome Atlas (TCGA). Notably, it is known that this cancer type frequently 302 
harbors amplified TP63 (Lawrence et al., 2015). We find that expression levels of our gene 303 
set indeed correlate significantly negatively with HNSC patient survival (COX likelihood ratio 304 
test p=0.032). To determine whether expression levels of the set have an influence on the 305 
survival of HNSC patients, we subdivided the samples according to the average expression 306 
levels into four equally sized groups (low, low-med, med-high, high). While the sample group 307 
with low expression had the most favorable prognosis, the null hypothesis could not be 308 
rejected in the direct comparison with patients with high average expression levels (p=0.090; 309 
Figure 8A). However, upon contrasting the low-expression group with all remaining samples, 310 
a significant improvement of survival was detected (p=0.024; Figure 8B). Expression of the 311 
28-gene set correlated positively with p63 expression when p63 expression was rather low 312 
(FPKM <20), but showed a saturation and no further correlation when p63 expression was 313 
high (FPKM >20; Figure 8C, 8D, and Figure 8-figure supplement 1). This indicates that p63 314 
levels influence the 28-gene set in a switch-like manner where a saturation of p63-dependent 315 
activation is quickly reached in HNSC cells. Together, these findings indicate that the genes 316 
commonly up-regulated by p63 and in SCC influence the prognosis of HNSC patients. Taken 317 
together, this finding calls for a more detailed assessment of ubiquitous p63/SCC genes as 318 




Although p63 (ΔNp63) is known as master regulator in epidermis development and 323 
more recently emerged as a key oncogenic factor in SCC, a comprehensive assessment of 324 
the GRN commonly controlled by p63 and its comparison to the GRN commonly controlled 325 
by the closely related tumor suppressor p53 has been missing. An increasing number of 326 
available high-throughput datasets enabled us to generate ranked lists of p63-regulated 327 
genes and p63 bound DNA sites that together reveal high-probability direct p63 target genes 328 
regulated by p63 across cells of multiple origins. Because p63 target genes, very much like 329 
p53 target genes (Fischer, 2020, 2019), differ substantially between mouse and human 330 
(Sethi et al., 2017), many p63 target genes initially described in mouse could not be 331 
confirmed to be p63-regulated in this study using human data. Given that p63 binding sites 332 
are frequently associated with enhancer regions and enhancer identity, we have integrated 333 
enhancer:gene associations to identify target genes that are regulated by p63 through direct 334 
binding to associated enhancers. This approach enabled the identification of novel direct 335 
target genes that are missed by standard analyses that employ only TSS proximity (Table 1 336 
and Figure 7-figure supplement 1). 337 
Given the similarity between their DBDs, it has been a long-standing question how 338 
p53 and p63 bind to distinct sites in the genome and how these sites differ from another. 339 
Several studies found differences in the biochemical properties of p53 and p63 that could 340 
affect their DNA binding specificity (Enthart et al., 2016; Lokshin et al., 2007; Sauer et al., 341 
2008; Tichý et al., 2013). Various studies aimed to identify the precise p63 recognition motif 342 
and its difference from the p53RE using either SELEX (Ortt and Sinha, 2006; Perez et al., 343 
2007) or ChIP-seq data (Kouwenhoven et al., 2010; McDade et al., 2014; Yang et al., 2006), 344 
yet these studies reported different features as being unique for p63 compared to p53 DNA 345 
recognition. By combining multiple ChIP-seq datasets we have contributed here to better 346 
distinguish between sites commonly bound by p53 and p63 across cell types and sites that 347 
are unique to p53 or p63 (Figure 5E). Most importantly, our results could explain why a 348 
substantial fraction of DNA sites is occupied exclusively by p53 or p63. While most sites 349 
bound by p53 are also commonly occupied by p63 (Figure 5E and Figure 5-figure 350 
supplement 1A), single half-sites and half-sites separated by spacers underlie many sites 351 
that are only bound by p53 (Figure 5F and 6), supporting earlier findings whereby p53 can be 352 
recruited through spacer-containing motifs (Vyas et al., 2017). However, while spacers 353 
reportedly have been identified in fifty percent of 200 analyzed p53REs (Vyas et al., 2017), 354 
our genome-wide quantification of motifs underlying 7705 high confidence p53 peaks based 355 
on an unbiased motif search using HOMER revealed that only 1.1 to 5.1% of the p53 peaks 356 
contain p53REs with 1 bp spacers or half sites that are possibly separated by longer spacers 357 
(Figure 6). Mechanistically, our results imply that relying on the CWWG core motif and the 358 
flanking regions may enable p53 to bind to those sites. In contrast, the two CNNG core 359 
motifs that underlie p63, but not p53REs, offer an explanation why a substantial fraction of 360 
DNA sites is bound exclusively by p63 (Figure 5F and 7), supporting one of the models 361 
established earlier (McDade et al., 2014). Notably, p63’s ability to bind to a greater variety of 362 
recognition motifs likely underlies the markedly greater number of p63 compared to p53 363 
binding sites in the genome. In addition, our motif search indicates that factors bound to AP-1 364 
(bZIP) and bHLH motifs may specifically support p63 binding (Figure 5-figure supplement 3), 365 
and transcription factor enrichment analysis identified the bZIP TF MAF, the TF GRHL2, the 366 
chromatin remodeler BANF1, the histone methyltransferase PRMT1, and the 367 
ZNF750/KDM1A/KLF4 complex, which was previously shown to operate downstream of p63 368 
(Boxer et al., 2014), as potential co-binders that could help to facilitate p63 binding to certain 369 
genomic loci (Figure 5-figure supplement 4). Considering its pioneer role, p63 could vice 370 
versa enable the binding of these TFs to the respective loci. Given that p63 and p73 form 371 
stable heterotetramers (Gebel et al., 2016), p73 may possess binding specificities that are 372 
highly similar to those identified for p63. Our results indicate that our approach could serve 373 
as a blueprint to distinguish DNA recognition motifs, binding sites, co-factors, and target 374 
genes of TF siblings more precisely. Our iterative de novo search algorithm enabled the 375 
identification of spacer-containing p53REs, indicating that our approach uncovers second-tier 376 
TF binding motifs invisible to standard approaches. Moreover, the results provide insights to 377 
the p63 DNA binding repertoire in unprecedented depth (Figure 5F). 378 
Consistent with results from an earlier genome-wide study (Yang et al., 2006), our 379 
findings imply that p63 is more frequently involved in a direct up-regulation as opposed to a 380 
direct down-regulation of target genes (Figure 3A and Figure 7-figure supplement 1). 381 
Mechanistically, p63 has been shown to up-regulate target genes through its alternative TAD 382 
located at the N-terminus while the C-terminus is important for down-regulation (Helton et al., 383 
2006). Exogenous expression of different isoforms of p53 family members and their 384 
antagonistic effects on target gene promoters in luciferase reporter assays suggested a 385 
model whereby p63 exhibits a dominant negative effect on other p53 family members (Mundt 386 
et al., 2010; Westfall et al., 2003; Yang et al., 1998). Inconsistent with its reputation as 387 
dominant negative regulator of p53, however, genome-wide studies showed that the groups 388 
of p63-regulated genes and p53-regulated genes show only very little overlap (Gallant-Behm 389 
et al., 2012). A recent analysis of DNA sites bound and of genes regulated by p53 and p63 390 
revealed that p63 is more likely to support than to inhibit p53 activity (Karsli Uzunbas et al., 391 
2019). Our analysis further supports the notion that p63 does not commonly interfere with 392 
target gene up-regulation by p53 but that except for cell cycle genes they regulate largely 393 
distinct gene sets (Figure 4). 394 
We identify several candidate TFs that may operate downstream of p63 and that may 395 
serve as transitional nodes in the p63 GRN. In addition to known mediators of p63-396 
dependent gene regulation, such as MYC and KLF4, we identify AR and its co-factor ZMIZ1, 397 
SP1, FLI1, and NANOG as novel candidate nodes in the p63 GRN (Figure 3A). In agreement 398 
with the tumor suppressor role of p53 and the oncogenic role of p63, we find that cell cycle 399 
genes are antagonistically regulated by p53 and p63 (Figure 2A and 4A). On the one hand, 400 
cell cycle genes are well-known to be down-regulated by p53 indirectly through the cyclin-401 
dependent kinase inhibitor p21 and the cell cycle repressor complexes DREAM and RB-E2F 402 
(Fischer et al., 2016a, 2016b; Schade et al., 2019; Uxa et al., 2019). On the other hand, cell 403 
cycle genes are down-regulated upon loss of p63 and this p63-dependent regulation 404 
reportedly occurs through regulating p21 signaling and the DREAM component p130 405 
(McDade et al., 2011; Truong et al., 2006). In addition to indirect effects, we also predicted 406 
multiple cell cycle genes as direct p63 targets (Table 1). Consequently, a loss of p63 may 407 
substantially contribute to the effect of p53 in reducing cell cycle gene expression (Figure 408 
3D). In addition of p63’s role in driving the expression of some cell cycle genes, the entire set 409 
of cell cycle genes may be subsequently up-regulated indirectly through p63’s pro-410 
proliferative targets. While the up-regulation of cell cycle genes occurs in most cancers 411 
(Whitfield et al., 2006), we find that p63 additionally regulates genes that are specifically 412 
altered across SCCs (Figure 2D). These results underscore the critical role of p63 and its 413 
target genes in determining the transcriptional profile of SCC. An example of a p63 target in 414 
SCC is NRG1, which can be inhibited to block SCC proliferation and tumor growth (Hegde et 415 
al., 2019). The resource of genes commonly regulated by p63 provided here may help to 416 
identify targets that can be exploited therapeutically. We provided a showcase example, 417 
where expression levels of the 28 p63 target genes that are commonly up-regulated by p63 418 
and in SCC (Table 1) correlate significantly with poorer survival of HNSC patients (Figure 8). 419 
Thus, this 28-gene set may contain particularly promising candidates for therapeutic 420 
interventions and for the use as biomarkers. 421 
  422 
Methods 423 
 424 
Re-analysis and integration of publicly available gene expression profiling datasets 425 
We re-analyzed publicly available p63-dependent gene expression profiling datasets. 426 
As a first quality requirement, we only included datasets for re-analysis that contained at 427 
least two biological replicates for the treatment as well as for the control condition. All 428 
microarray datasets were available at a pre-processed stage at the Gene Expression 429 
Omnibus (GEO) and we re-analyzed these datasets with GEO2R to obtain fold expression 430 
changes and Benjamini Hochberg-corrected p-values (Clough and Barrett, 2016). Gene 431 
identifiers were mapped to Ensembl Gene IDs using the Ensembl annotation data 432 
(Cunningham et al., 2019). All RNA-seq datasets have been retrieved through GEO from the 433 
Sequence Read Archive (SRA) (Leinonen et al., 2011). We employed our RNA-seq analysis 434 
pipeline to obtain fold expression changes and p-values adjusted for multiple testing. Briefly, 435 
we utilized Trimmomatic (Bolger et al., 2014) v0.39 (5nt sliding window approach, mean 436 
quality cutoff 22) for read quality trimming according to inspections made from FastQC 437 
(https://www.bioinformatics.babraham.ac.uk/projects/fastqc/) v0.11.8 reports. Clipping was 438 
performed using Cutadapt v2.3 (Martin, 2011). Potential sequencing errors were detected 439 
and corrected using Rcorrector v1.0.3.1 (Song and Florea, 2015). Ribosomal RNA (rRNA) 440 
transcripts were artificially depleted by read alignment against rRNA databases through 441 
SortMeRNA v2.1 (Kopylova et al., 2012). The preprocessed data was aligned to the 442 
reference genome hg38, retrieved along with its gene annotation from Ensembl v.92 443 
(Cunningham et al., 2019). For read alignment, we used the splice-aware mapping software 444 
segemehl (Hoffmann et al., 2014, 2009) v0.3.4 with adjusted accuracy (95%). Mappings 445 
were filtered by Samtools v1.9 (Li et al., 2009) for uniqueness and properly aligned mate 446 
pairs. Read quantification was performed on exon level using featureCounts v1.6.5 (Liao et 447 
al., 2014), parametrized according to the strand specificity inferred through RSeQC v3.0.0 448 
(Wang et al., 2012). Differential gene expression and its statistical significance was identified 449 
using DESeq2 v1.20.0 (Love et al., 2014). Information on the samples that were compared 450 
for each dataset is included in Supplementary File 1. Given that all RNA-seq data was 451 
derived from PolyA-enriched samples, we only included Ensembl transcript types 452 
‘protein_coding’, ‘antisense’, ‘lincRNA’ and ‘TEC’ in our analysis. Common thresholds for adj. 453 
p-value ≤ 0.05 were applied. 454 
 455 
Generation of the p63 Expression Score 456 
For 19,156 genes covered by at least three datasets including a minimum of one 457 
RNA-seq dataset, a p63 Expression Score was calculated as the number of datasets that 458 
find the gene to be significantly up-regulated minus the number of datasets that find the gene 459 
to be significantly down-regulated in dependence on p63. This meta-analysis resulted in 27 460 
p63 Expression Score gene groups because no gene was identified as up-regulated in all 16 461 
or 15 datasets or down-regulated in all 16, 15, 14 or 13 datasets. 462 
 463 
Enrichment analyses 464 
Gene set enrichment analysis (GSEA) was performed using GSEA 465 
(http://software.broadinstitute.org/gsea/) with ‘H’, ‘C2’, and ‘C6’ gene sets from MSigDB v7.0 466 
(Subramanian et al., 2005) and custom panSCC gene sets derived from Table S1C in 467 
Campbell et al. (Campbell et al., 2018). GSEA was performed on a pre-ranked list of genes 468 
that were ranked primarily by p63 Expression Score and secondarily by median log2(fold-469 
change) to obtain unique ranks. 470 
Enrichment of transcription factor binding to genes with high (≥ 8) or low (≤ -8) p63 471 
Expression Score was identified using the results section ‘ENCODE and ChEA Consensus 472 
TFs from ChIP-X’ from Enrichr (Kuleshov et al., 2016). 473 
 474 
Integration of publicly available p63 and p53 binding data  475 
Peak datasets from p63 ChIP-seq experiments were retrieved from CistromeDB (R. 476 
Zheng et al., 2019) (Supplementary File 1). When replicate experiments were available, all 477 
peaks were used that have been identified in at least two replicates. A similar collection of 478 
p53 peak datasets has been described previously (Fischer, 2019). To intersect multiple peak 479 
files Bedtools ‘multiinter’ was used and to identify overlapping and non-overlapping peaks 480 
Bedtools ‘intersect’ was employed (Quinlan and Hall, 2010). 481 
 482 
Motif search 483 
Known p53 and p63REs were identified using the ‘known motifs’ in HOMER v4.10 484 
with default options and -size given (Heinz et al., 2010). De novo motif discovery was 485 
performed with options -size given -len 10,15,20,25 -mis 5 -S 10. 486 
 487 
Identification of potential co-factors 488 
We used the CistromeDB toolkit (R. Zheng et al., 2019) to identify TFs that display 489 
ChIP-seq peaksets that are significantly similar to our ‘unique p53’, ‘unique p63’, and 490 
‘p53+p63’ peaksets. 491 
 492 
Survival and expression correlation analysis 493 
For the 28-gene set, single-sample enrichment scores were derived from FPKM 494 
normalized gene expression values of 546 HNSC patient samples. To this end, we utilized 495 
the official GenePattern single sample gene set enrichment analysis (ssGSEA) codebase 496 
v10.0.3 (https://github.com/GSEA-MSigDB/ssGSEA-gpmodule). A sample score represents 497 
the coordinately up- or down-regulated expression of all genes within one set as its signature 498 
(Barbie et al., 2009). Kaplan-Meier plots and correlation analyses were performed on TCGA 499 
time to event and event occurrence information using the R survival package v3.2-3. 500 
Following the TCGA standard for HNSC (Lawrence et al., 2015), survival analyses were 501 
right-censored at 60 months (1800 days) to avoid non-cancer-related events. The Cox 502 
proportional hazards model was used to investigate the association of patient survival time 503 
and the combined expression levels of the 28-gene set. Subsequently, we subdivided the 504 
expression scores into four equally sized categorical groups (high, med-high, med-low, low). 505 
The rates of occurrence of events over time were compared between these groups using the 506 
fitted COX PH model. 507 
We retrieved read quantification data 'HTSeq - Counts' from 546 samples of the 508 
TCGA project HNSC utilizing the R package TCGAbiolinks v2.18.0 (Colaprico et al., 2016). 509 
Per sample, all read counts of the 28-gene set were merged into an artificially created 510 
metagene. Subsequently, we calculated normalized expression values per gene as 511 
fragments per kilobase million, where the length of a gene corresponds to the lengths of its 512 
exons assigned to either the canonical transcript (CCDS) or the longest transcript according 513 
to hg38 Ensembl annotation v92. TP63 FPKM values were plotted against the meta-gene 514 
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 1064 
Figure 1 1065 
Meta-analysis of p63-dependent gene regulation. (A) Distribution of the number of 1066 
genes found in each of the p63 Expression Score groups. Because p63 Expression Score 1067 
group ‘13’ and ‘-12’ contained only 2 genes they were included in group ‘12’ and ‘-11’, 1068 
respectively, for further analyses. (B) 16 datasets on p63-dependent gene expression from 1069 
11 studies. EE – exogenous p63 expression; sh KD – shRNA-mediated knockdown; si KD – 1070 
siRNA-mediated knockdown; KO - sgRNA-mediated knockout (C) A heatmap displaying the 1071 
regulation of 15 genes with positive and 15 genes with negative p63 Expression Scores. 1072 
GAPDH and GAPDHS represent negative controls. 1073 
 1074 
Figure 2 1075 
Gene sets enriched among genes commonly regulated by p63. Enrichment of (A, 1076 
B, C, E) MSigDB gene sets or (D) genes up- and down-regulated across squamous cell 1077 
cancers (SCC) (Campbell et al., 2018) among genes ranked by the p63 Expression Score. 1078 
 1079 
Figure 3 1080 
Transcription factors in the p63 GRN. (A) Significant (adj.p-value ≤ 0.05) enrichment 1081 
of TF binding at genes with a p63 Expression Score ≥ 8 (green) or ≤ -8 (red) as identified by 1082 
Enrichr (Kuleshov et al., 2016). (B) Enrichment of MSigDB gene sets among genes ranked 1083 
by the p63 Expression Score. Scatter plots displays the log
2
(fold-change) of previously 1084 
collected high confidence DREAM target genes (Fischer et al., 2016a) (C) across the 16 p63-1085 
dependent gene expression profiling datasets and (D) MCF10A cells treated with DMSO or 1086 
Nutlin in addition to shControl and shp63 (Karsli Uzunbas et al., 2019). CDKN1A levels serve 1087 
as control. The black line indicates the median. 1088 
 1089 
Figure 4 1090 
p63 and p53 regulate largely distinct target gene sets. (A) The p63 Expression 1091 
Score compared to the previously published p53 Expression Score that was generated using 1092 
the same meta-analysis approach (Fischer et al., 2016a) for all 16,198 genes for which both 1093 
scores were available. (B) The scatter plot displays the log2(fold-change) of previously 1094 
collected high confidence direct p53 target genes (Fischer, 2017) across the 16 p63-1095 
dependent gene expression profiling datasets. The black line indicates the median. The data 1096 
indicates a large degree of independence of p53 targets from p63-dependent expression. 1097 
 1098 
Figure 5 1099 
The p63 and p53 DNA binding landscape. (A and B) The number of p63 and p53 1100 
binding peaks sorted by the number of datasets that commonly identified/support the peak. 1101 
(C) The number of p53 and p63 peaks identified in the 28 p53 and 20 p63 ChIP-seq 1102 
datasets, respectively. (D) The relative number of ‘known’ p53 and p63 motifs found by 1103 
HOMER v4.10 (Heinz et al., 2010) under p53 and p63 peaks, respectively, with increasing 1104 
dataset support. (E) Schematic of ‘p53’, ‘p63’ and ‘p53+p63’ peak selection for further 1105 
analyses. (F) De novo motif search results from HOMER v4.10 (Heinz et al., 2010) for the 1106 
‘p53+p63’, ‘p53’, and ‘p63’ peak sets. The first round of motif search identified the ‘primary’ 1107 
motif in each peak set. Using an iterative approach, all peaks that contained the ‘primary’ 1108 
motif were removed and the de novo motif search was repeated. This iterative approach was 1109 
followed until no more p53/p63-like motif was identified. 1110 
 1111 
Figure 6 1112 
The DNA binding landscape of p53. DNA sites occupied by p53 in at least 5 1113 
datasets were searched iterative with the motifs identified by our iterative de novo search 1114 
(Figure 5F). We searched first for the primary ‘p53+p63’ motif and among all remaining sites 1115 
for the primary ‘p53’ motif. All other ‘p53+p63’ and ‘p53’ motifs were searched subsequently. 1116 
 1117 
Figure 7 1118 
The DNA binding landscape of p63. DNA sites occupied by p63 in at least 5 1119 
datasets were searched iterative with the motifs identified by our iterative de novo search 1120 
(Figure 5F). We searched first for the primary ‘p53+p63’ motif and among all remaining sites 1121 
for the primary ‘p63’ motif. All other ‘p53+p63’ and ‘p63’ motifs were searched subsequently 1122 
(Supplementary File 3). 1123 
 1124 
Figure 8 1125 
p63/SCC 28-gene set correlates with poorer survival in HNSC. Kaplan-Meier plots 1126 
of TCGA HNSC patient survival data. (A) Patients were subdivided in four equally sized 1127 
subgroups based on expression levels of the 28-gene set. The results suggest a poorer 1128 
survival of patients with an up-regulated expression of the set genes. (B) To corroborate this 1129 
finding patients of the subgroups low-med, med-high, and high from (A) were joined to form a 1130 
new high group. Boxplot in bins of 10 of TP63 FPKM expression values in TCGA HNCS 1131 
patient sample data compared to (C) FPKM values of a meta-gene comprising the 28-gene 1132 
set and (D) ssGSEA scores of the 28-gene set. X-axis is right-censored at 100 to better 1133 
visualize the effect. The full graph is displayed in Figure 8-figure supplement 1. 1134 
 1135 
Figure 5-figure supplement 1 1136 
(A and B) Correlation between dataset support for p53 and p63 binding. (C to F) 1137 
Correlation between HOMER motif score for primary and secondary ‘p53+p63’ motifs and 1138 
dataset support for (C and D) p53 binding or (E and F) p63 binding. 1139 
 1140 
Figure 5-figure supplement 2 1141 
Correlation between HOMER motif score for primary, secondary and tertiary (A to C) 1142 
‘p53’ motifs or (D to F) ‘p63’ motifs and dataset support for (A to C) p53 binding or (D to F) 1143 
p63 binding. 1144 
 1145 
Figure 5-figure supplement 3 1146 
Top motifs co-enriched with primary ‘p53+p63’, ‘p53’, and ‘p63’ motifs at the respective 1147 
DNA sites. 1148 
 1149 
Figure 5-figure supplement 4 1150 
Top 20 TFs with ChIP-seq peak sets similar to (A) the common p53+p63 sites, (B) the 1151 
unique p53 sites, and (C) the unique p63 sites (Figure 5E) as identified using CistromeDB 1152 
toolkit. Of note, some TP53 ChIP-seq datasets are wrongly labeled “T” in the database. 1153 
 1154 
Figure 7-figure supplement 1 1155 
Complement to Table 1. Genes identified as significantly up- or down-regulated in at 1156 
least the half of all datasets (|p63 Expression Score| ≥ 8) that are linked to p63 binding sites 1157 
supported by at least half of all datasets (≥ 10) through binding within 5 kb from their TSS or 1158 
through double-elite enhancer:gene associations (Fishilevich et al., 2017). Using these 1159 
thresholds we identified 138 and 42 high-probability candidates as directly up- and down-1160 
regulated by p63, respectively. Gene names marked in red are also up- or down-regulated 1161 
across SCCs (Campbell et al., 2018). 1162 
 1163 
Figure 8-figure supplement 1 1164 
Boxplot in bins of 10 of TP63 FPKM expression values in TCGA HNCS patient sample 1165 
data compared to (A) FPKM values of a meta-gene comprising the 28-gene set and (B) 1166 
ssGSEA scores of the 28-gene set. Complementary to Figure 8C and D. 1167 
 1168 
Supplementary File 1 1169 
Detailed information on publicly available p63-dependent gene expression profiling 1170 
and p63 ChIP-seq datasets that were integrated in this study. 1171 
 1172 
Supplementary File 2 1173 
Meta-analysis from 16 p63-dependent gene expression information datasets (listed in 1174 
Suppelemtary File 1) to generate the p63 Expression Score for 19,156 human genes. 1175 
 1176 
Supplementary File 3 1177 
p63 and p53 binding sites identified in at least 5 out of 20 and 28 ChIP-seq datasets, 1178 
respectively. Binding sites are listed with their ChIP-seq dataset support and highest scoring 1179 
p63 response elements (p63REs) or p53REs. Genes associated with p63 binding sites 1180 
through proximal TSS binding or enhancers are listed. 1181 
 1182 























# genes sig. regulated










si KD KC 17,883 1,951 3,396
Wu 2012 si KD HaCaT microarray 11,580 1,046 873
Gallant-Behm 
2012
sh KD H226 microarray 16,470 2,264 1,890
Watanabe 2014 sh KD KYSE70 RNA-seq 12,866 354 580





sh KD FaDu 16,403 1,512 1,057
Abraham 2018 sh KD H226 RNA-seq 15,984 4,053 4,550
Somerville 2018
sh KD / KO BxPC3
RNA-seq
16,153 871 1,373





sh KD +Nutlin MCF10A 13,180 2,940 2,198
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Spearman r 0.36 Spearman r 0.34
(A and B) Correlation between data set support for p53 and p63 binding. (C to F) Correlation between HOMER motif
score for primary and secondary ‘p53+p63’ motifs and data set support for (C and D) p53 binding or (E and F) p63 binding















































































































































Correlation between HOMER motif score for primary, secondary and tertiary (A to C) ‘p53’ motifs or
(D to F) ‘p63’ motifs and data set support for (A to C) p53 binding or (D to F) p63 binding.
Motif p-value % targets % background similarity
1E-6729 74.84% 0.90% p53
1E-382 3.04% 0.01% unknown
1E-256 1.95% 0.00% GATA
Riege et al., Figure 5 – figure supplement 3




Motif p-value % targets % background similarity
1E-662 52.63% 1.38% p53
1E-163 6.08% 0.01% unknown
1E-131 5.56% 0.01% GATA
Motif p-value % targets % background similarity
1E-11463 65.20% 4.46% p63
1E-761 23.99% 9.32% AP-1 (bZIP)
1E-525 36.63% 21.03% bHLH
Top motifs co-enriched with primary ‘p53+p63’, ‘p53’, and ‘p63’ motifs at the respective DNA sites.
Riege et al., Figure 5 – figure supplement 4
Top 20 TFs that possess ChIP-seq peaksets similar to (A) the common p53+p63 sites, (B) the unique p53 sites, and
(C) the unique p63 sites (Figure 5E) as identified using CistromeDB toolkit. Of note, some TP53 ChIP-seq data sets are
wrongly labeled “T” in the database.
B
A common p53+p63 binding sites
unique p53 binding sites
C unique p63 binding sites








p53+p63 primary p53 primary
p53+p63 secondary p53 secondary
p53 tertiary p53+p63 quarternary
p53+p63 quinary other
p53 DNA binding landscape
7,705 p53 peaks supported by ≥ 5 data sets
p63 DNA binding landscape













p53+p63 primary p63 primary p53+p63 secondary
p63 secondary p63 tertiary p53+p63 quarternary
p63 quarternary p53+p63 quinary p63 quinary
p63 senary p63 septary other
Riege et al., Figure 7




































































































































































































































Figure 7 – figure supplement 1
Complement to Table 1. Genes identified as significantly up- or down-regulated in at least the half of all datasets (|p63
Expression Score| ≥ 8) that are linked to p63 binding sites supported by at least half of all datasets (≥ 10) through binding within
5 kb from their TSS or through double-elite enhancer:gene associations (Fishilevich et al., 2017). Using these thresholds we
identified 138 and 42 high-probability candidates as directly up- and down-regulated by p63, respectively. Gene names marked
in red are also up- or down-regulated across SCCs (Campbell et al., 2018).
Riege et al., Figure 8
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Riege et al., Figure 8 – figure supplement 1
BA
Boxplot in bins of 10 of TP63 FPKM expression values in TCGA HNCS patient sample data compared to (A) FPKM 
values of a meta-gene comprising the 28-gene set and (B) ssGSEA scores of the 28-gene set. Complementary to Figure 
8C and D.
